434 related articles for article (PubMed ID: 28687621)
1. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.
Borriello L; Nakata R; Sheard MA; Fernandez GE; Sposto R; Malvar J; Blavier L; Shimada H; Asgharzadeh S; Seeger RC; DeClerck YA
Cancer Res; 2017 Sep; 77(18):5142-5157. PubMed ID: 28687621
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.
Pelizzo G; Veschi V; Mantelli M; Croce S; Di Benedetto V; D'Angelo P; Maltese A; Catenacci L; Apuzzo T; Scavo E; Moretta A; Todaro M; Stassi G; Avanzini MA; Calcaterra V
BMC Cancer; 2018 Nov; 18(1):1176. PubMed ID: 30482160
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
4. CXCR4/TGF-β1 mediated self-differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and promoted colorectal carcinoma development.
Tan HX; Xiao ZG; Huang T; Fang ZX; Liu Y; Huang ZC
Cancer Biol Ther; 2020; 21(3):248-257. PubMed ID: 31818187
[No Abstract] [Full Text] [Related]
5. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
Healy JR; Hart LS; Shazad AL; Gagliardi ME; Tsang M; Elias J; Ruden J; Farrel A; Rokita JL; Li Y; Wyce A; Barbash O; Batra V; Samanta M; Maris JM; Schnepp RW
Pediatr Blood Cancer; 2020 Jun; 67(6):e28267. PubMed ID: 32307821
[TBL] [Abstract][Full Text] [Related]
6. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
7. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development.
Hashimoto O; Yoshida M; Koma Y; Yanai T; Hasegawa D; Kosaka Y; Nishimura N; Yokozaki H
J Pathol; 2016 Oct; 240(2):211-23. PubMed ID: 27425378
[TBL] [Abstract][Full Text] [Related]
8. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
[TBL] [Abstract][Full Text] [Related]
9. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway.
Wang Y; Jing Y; Ding L; Zhang X; Song Y; Chen S; Zhao X; Huang X; Pu Y; Wang Z; Ni Y; Hu Q
J Exp Clin Cancer Res; 2019 Jun; 38(1):274. PubMed ID: 31234944
[TBL] [Abstract][Full Text] [Related]
10. A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma.
Silverman AM; Nakata R; Shimada H; Sposto R; DeClerck YA
Cancer Res; 2012 May; 72(9):2228-38. PubMed ID: 22389450
[TBL] [Abstract][Full Text] [Related]
11. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis.
Pradhan R; Paul S; Acharya SS; Sinha S; Dash SR; Kundu CN
J Nutr Biochem; 2024 Mar; 125():109568. PubMed ID: 38185347
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition.
Pietrovito L; Leo A; Gori V; Lulli M; Parri M; Becherucci V; Piccini L; Bambi F; Taddei ML; Chiarugi P
Mol Oncol; 2018 May; 12(5):659-676. PubMed ID: 29517849
[TBL] [Abstract][Full Text] [Related]
13. Intracellular Notch1 Signaling in Cancer-Associated Fibroblasts Dictates the Plasticity and Stemness of Melanoma Stem/Initiating Cells.
Du Y; Shao H; Moller M; Prokupets R; Tse YT; Liu ZJ
Stem Cells; 2019 Jul; 37(7):865-875. PubMed ID: 30941836
[TBL] [Abstract][Full Text] [Related]
14. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium.
Gao H; Priebe W; Glod J; Banerjee D
Stem Cells; 2009 Apr; 27(4):857-65. PubMed ID: 19350687
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways.
Choi SC; Kim SJ; Choi JH; Park CY; Shim WJ; Lim DS
Stem Cells Dev; 2008 Aug; 17(4):725-36. PubMed ID: 18788932
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3/AUF1 pathway.
Al-Jomah N; Al-Mohanna FH; Aboussekhra A
Carcinogenesis; 2021 Dec; 42(12):1439-1448. PubMed ID: 34718441
[TBL] [Abstract][Full Text] [Related]
17. Adipose-derived mesenchymal stem cells differentiate into pancreatic cancer-associated fibroblasts in vitro.
Miyazaki Y; Oda T; Mori N; Kida YS
FEBS Open Bio; 2020 Nov; 10(11):2268-2281. PubMed ID: 32931156
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
20. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
Yeung TL; Sheng J; Leung CS; Li F; Kim J; Ho SY; Matzuk MM; Lu KH; Wong STC; Mok SC
J Natl Cancer Inst; 2019 Mar; 111(3):272-282. PubMed ID: 29860390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
